EGFR and cancer: The same group showed TUFM-NLRX1 interaction also in cancer cells, in which NLRX1 promoted cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, -induced autophagy and mediated resistance to cancer treatment (Lei et al., 2016).